Jamal Hill
YOU?
Author Swipe
View article: Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer
Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer Open
Prophylactic treatment with selective estrogen receptor modulators (SERMs) and aroma-tase inhibitors (AIs) targeting the nuclear estrogen receptor (ER) can prevent the formation of ER-positive tumors in women at high risk for breast cancer…
View article: Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer Cells
Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer Cells Open
Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of tumor protein 53 (TP53) mutation and with limited targeted therapies. Despite being clinically advantageous, direct ta…
View article: Supplementary Figure S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line gene expression
View article: Supplementary Table S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Table S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary table listing qPCR primers and probes used in methods
View article: Supplementary Figure S3 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S3 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with representative cell cycle progression
View article: Supplementary Figure S5 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S5 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line protein expression
View article: Supplementary Figure S4 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S4 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line apoptosis rescue
View article: Supplementary Figure S7 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S7 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional drug synergy models using TKI
View article: Supplementary Figure S8 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S8 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional drug synergy models using ADC
View article: Supplementary Figure S6 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S6 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional cell line growth assays of drug combinations
View article: Supplementary Figure S2 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S2 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line drug sensitivity
View article: Supplementary Figure S2 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S2 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line drug sensitivity
View article: Supplementary Figure S6 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S6 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional cell line growth assays of drug combinations
View article: Supplementary Figure S7 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S7 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional drug synergy models using TKI
View article: Supplementary Figure S4 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S4 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line apoptosis rescue
View article: Data from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Data from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Purpose:Rexinoids, agonists of nuclear retinoid X receptor (RXR), have been used for the treatment of cancers and are well tolerated in both animals and humans. However, the usefulness of rexinoids in treatment of breast cancer remains unk…
View article: Supplementary Figure S3 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S3 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with representative cell cycle progression
View article: Data from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Data from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Purpose:Rexinoids, agonists of nuclear retinoid X receptor (RXR), have been used for the treatment of cancers and are well tolerated in both animals and humans. However, the usefulness of rexinoids in treatment of breast cancer remains unk…
View article: Supplementary Figure S8 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S8 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with additional drug synergy models using ADC
View article: Supplementary Table S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Table S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary table listing qPCR primers and probes used in methods
View article: Supplementary Figure S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S1 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line gene expression
View article: Supplementary Figure S5 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Supplementary Figure S5 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Supplementary figure with cell line protein expression
View article: IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy Open
Purpose: Rexinoids, agonists of nuclear retinoid X receptor (RXR), have been used for the treatment of cancers and are well tolerated in both animals and humans. However, the usefulness of rexinoids in treatment of breast cancer remains un…
View article: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth Open
Background The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal grow…
View article: Supplementary Figure 4 from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis
Supplementary Figure 4 from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis Open
Expression of SOX9 in Curtis breast cancer dataset and NEVE breast cancer cell lines
View article: Related Article from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
Related Article from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib Open
Related Article from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
View article: Supplementary Figure 9 from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis
Supplementary Figure 9 from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis Open
SOX9 controls G0/G1 to S phase cell cycle
View article: Data from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis
Data from SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis Open
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancers, and lacks effective targeted treatment strategies. Previously, we identified 33 transcription factors highly expressed in TNBC. Here, we focused on six sex…